S&P 500   3,841.94
DOW   31,496.30
QQQ   308.68
pixel
pixel
pixel
S&P 500   3,841.94
DOW   31,496.30
QQQ   308.68
pixel
pixel
pixel
S&P 500   3,841.94
DOW   31,496.30
QQQ   308.68
pixel
pixel
pixel
S&P 500   3,841.94
DOW   31,496.30
QQQ   308.68
pixel
pixel
pixel
Log in
NASDAQ:AMPH

Amphastar Pharmaceuticals Stock Forecast, Price & News

$17.52
+0.31 (+1.80 %)
(As of 03/5/2021 12:00 AM ET)
Add
Compare
Today's Range
$17.11
Now: $17.52
$17.57
50-Day Range
$17.21
MA: $18.48
$19.26
52-Week Range
$12.32
Now: $17.52
$22.69
Volume222,200 shs
Average Volume212,537 shs
Market Capitalization$832.27 million
P/E Ratio125.14
Dividend YieldN/A
Beta0.87
Amphastar Pharmaceuticals, Inc., a specialty pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. The company operates through two segments, Finished Pharmaceutical Products and API. It offers enoxaparin, a low molecular weight heparin to prevent and treat deep vein thrombosis; naloxone for opioid overdose; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; and Cortrosyn, a lyophilized powder use as a diagnostic agent in the screening of patients with adrenocortical insufficiency. The company also provides Amphadase, a bovine-sourced hyaluronidase injection to absorb and disperse other injected drugs; lidocaine jelly, a local anesthetic product for urological procedures; lidocaine topical solution for various procedures; phytonadione injection for newborn babies; atropine, calcium chloride, dextrose, epinephrine, lidocaine, and sodium bicarbonate for emergency use in hospital settings; morphine injection; and lorazepam injection for surgery and medical procedures. In addition, it offers procainamide for documented ventricular arrhythmias; neostigmine methylsulfate injection to treat myasthenia gravis and to reverse the effects of muscle relaxants; medroxyprogesterone acetate injectable suspension for the prevention of pregnancy; and Isoproterenol hydrochloride injection for mild or transient episodes of heart block, as well as recombinant human insulin API (active pharmaceutical ingredients) and porcine insulin API. Further, the company has a pipeline of 20 product candidates in various stages of development for various indications. It serves hospitals, care facilities, alternate care sites, clinics, and doctors' offices. The company was founded in 1996 and is headquartered in Rancho Cucamonga, California.
Amphastar Pharmaceuticals logo

Headlines

Amphastar Hikes on OK from FDA
December 29, 2020 |  marketwatch.com
Earnings Outlook For Amphastar Pharmaceuticals
November 5, 2020 |  finance.yahoo.com
See More Headlines

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:AMPH
CUSIPN/A
Phone909-980-9484
Employees2,027
Year FoundedN/A

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$322.36 million
Cash Flow$0.72 per share
Book Value$9.11 per share

Profitability

Net Income$48.94 million

Miscellaneous

Market Cap$832.27 million
Next Earnings Date3/11/2021 (Estimated)
OptionableOptionable

MarketRank

Overall MarketRank

1.69 out of 5 stars

Medical Sector

267th out of 1,968 stocks

Pharmaceutical Preparations Industry

123rd out of 771 stocks

Analyst Opinion: 3.1Community Rank: 2.6Dividend Strength: 0.0Insider Behavior: 0.8Valuation: 1.9 5 -4 -3 -2 -1 -
$17.52
+0.31 (+1.80 %)
(As of 03/5/2021 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive AMPH News and Ratings via Email

Sign-up to receive the latest news and ratings for AMPH and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Amphastar Pharmaceuticals (NASDAQ:AMPH) Frequently Asked Questions

Is Amphastar Pharmaceuticals a buy right now?

4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Amphastar Pharmaceuticals in the last twelve months. There are currently 3 hold ratings and 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "hold" Amphastar Pharmaceuticals stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in AMPH, but not buy additional shares or sell existing shares.
View analyst ratings for Amphastar Pharmaceuticals
or view top-rated stocks.

What stocks does MarketBeat like better than Amphastar Pharmaceuticals?

Wall Street analysts have given Amphastar Pharmaceuticals a "Hold" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Amphastar Pharmaceuticals wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is Amphastar Pharmaceuticals' next earnings date?

Amphastar Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Thursday, March 11th 2021.
View our earnings forecast for Amphastar Pharmaceuticals
.

How were Amphastar Pharmaceuticals' earnings last quarter?

Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) issued its quarterly earnings data on Wednesday, November, 11th. The company reported $0.15 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.14 by $0.01. The firm earned $83.43 million during the quarter, compared to the consensus estimate of $90.81 million. Amphastar Pharmaceuticals had a trailing twelve-month return on equity of 5.50% and a net margin of 1.97%.
View Amphastar Pharmaceuticals' earnings history
.

How has Amphastar Pharmaceuticals' stock price been impacted by COVID-19?

Amphastar Pharmaceuticals' stock was trading at $15.30 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, AMPH shares have increased by 14.5% and is now trading at $17.52.
View which stocks have been most impacted by COVID-19
.

What price target have analysts set for AMPH?

4 Wall Street analysts have issued 12 month price targets for Amphastar Pharmaceuticals' stock. Their forecasts range from $21.00 to $24.00. On average, they expect Amphastar Pharmaceuticals' share price to reach $22.00 in the next twelve months. This suggests a possible upside of 25.6% from the stock's current price.
View analysts' price targets for Amphastar Pharmaceuticals
or view top-rated stocks among Wall Street analysts.

Who are Amphastar Pharmaceuticals' key executives?

Amphastar Pharmaceuticals' management team includes the following people:
  • Dr. Ziping Luo, Chairman, Chief Scientist & COO (Age 71, Pay $1.3M)
  • Dr. Yongfeng Zhang, Co-founder, Pres, CEO, Chief Scientific Officer & Director (Age 74, Pay $1.99M)
  • Mr. William J. Peters, CFO, Treasurer & Sr. VP of Fin. (Age 53, Pay $907.01k)
  • Mr. Rong Zhou, Exec. VP of Production Center (Age 62, Pay $724.46k)
  • Mr. Jacob Liawatidewi M.B.A., Exec. VP of Corp. Admin. Center, Sales & Marketing and Corp. Sec. (Age 47)
  • Dan Dischner, VP of Corp. Communications
  • Tony Marrs, Sr. VP of Regulatory Affairs and Clinical Operations
  • Mr. Peter Langosh, VP of Operational Improvement and VP of Internal Audit (Age 68)
  • Ms. Eva Wen, Director of System Control

What is Jack Y. Zhang's approval rating as Amphastar Pharmaceuticals' CEO?

27 employees have rated Amphastar Pharmaceuticals CEO Jack Y. Zhang on Glassdoor.com. Jack Y. Zhang has an approval rating of 35% among Amphastar Pharmaceuticals' employees. This puts Jack Y. Zhang in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies.

Who are some of Amphastar Pharmaceuticals' key competitors?

What other stocks do shareholders of Amphastar Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Amphastar Pharmaceuticals investors own include Cara Therapeutics (CARA), Gilead Sciences (GILD), Amicus Therapeutics (FOLD), Exelixis (EXEL), CNX Resources (CNX), Immunomedics (IMMU), AbbVie (ABBV), Cellectis (CLLS), Clovis Oncology (CLVS) and Galectin Therapeutics (GALT).

What is Amphastar Pharmaceuticals' stock symbol?

Amphastar Pharmaceuticals trades on the NASDAQ under the ticker symbol "AMPH."

Who are Amphastar Pharmaceuticals' major shareholders?

Amphastar Pharmaceuticals' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (15.04%), Federated Hermes Inc. (6.79%), Dimensional Fund Advisors LP (3.80%), Fuller & Thaler Asset Management Inc. (1.15%), Northern Trust Corp (1.03%) and Morgan Stanley (0.70%). Company insiders that own Amphastar Pharmaceuticals stock include David Maris, Floyd F Petersen, Howard Lee, Jack Y Zhang, Jason B Shandell, Michael A Zasloff, Richard K Prins, Richard Koo, Rong Zhou, William J Peters and Yakob Liawatidewi.
View institutional ownership trends for Amphastar Pharmaceuticals
.

Which institutional investors are selling Amphastar Pharmaceuticals stock?

AMPH stock was sold by a variety of institutional investors in the last quarter, including Fuller & Thaler Asset Management Inc., Renaissance Technologies LLC, Sei Investments Co., Wells Fargo & Company MN, Skandinaviska Enskilda Banken AB publ , Northern Trust Corp, Rothschild & Co. Asset Management US Inc., and Nuveen Asset Management LLC. Company insiders that have sold Amphastar Pharmaceuticals company stock in the last year include Floyd F Petersen, Howard Lee, Jack Y Zhang, Michael A Zasloff, Richard K Prins, Richard Koo, Rong Zhou, William J Peters, and Yakob Liawatidewi.
View insider buying and selling activity for Amphastar Pharmaceuticals
or view top insider-selling stocks.

Which institutional investors are buying Amphastar Pharmaceuticals stock?

AMPH stock was acquired by a variety of institutional investors in the last quarter, including Federated Hermes Inc., BlackRock Inc., Morgan Stanley, First Trust Advisors LP, Tudor Investment Corp Et Al, Public Sector Pension Investment Board, Nisa Investment Advisors LLC, and JPMorgan Chase & Co..
View insider buying and selling activity for Amphastar Pharmaceuticals
or or view top insider-buying stocks.

How do I buy shares of Amphastar Pharmaceuticals?

Shares of AMPH can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Amphastar Pharmaceuticals' stock price today?

One share of AMPH stock can currently be purchased for approximately $17.52.

How much money does Amphastar Pharmaceuticals make?

Amphastar Pharmaceuticals has a market capitalization of $832.27 million and generates $322.36 million in revenue each year. The company earns $48.94 million in net income (profit) each year or $0.36 on an earnings per share basis.

How many employees does Amphastar Pharmaceuticals have?

Amphastar Pharmaceuticals employs 2,027 workers across the globe.

What is Amphastar Pharmaceuticals' official website?

The official website for Amphastar Pharmaceuticals is www.amphastar.com.

Where are Amphastar Pharmaceuticals' headquarters?

Amphastar Pharmaceuticals is headquartered at 11570 SIXTH STREET, RANCHO CUCAMONGA CA, 91730.

How can I contact Amphastar Pharmaceuticals?

Amphastar Pharmaceuticals' mailing address is 11570 SIXTH STREET, RANCHO CUCAMONGA CA, 91730. The company can be reached via phone at 909-980-9484 or via email at [email protected]


This page was last updated on 3/8/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.